We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 1.95% | 29.83 | 29.78 | 29.86 | 30.08 | 29.715 | 30.04 | 4,829,456 | 21:22:28 |
From May 2019 to May 2024
By Colin Kellaher
Roche Holding AG and PTC Therapeutics Inc. on Tuesday said the European Commission approved Evrysdi for the treatment of 5q spinal muscular atrophy, or SMA, in patients two months of age and older.
The companies said Evrysdi is approved for patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies, adding that the drug is the first and only at-home treatment approved for the disease.
SMA, a severe, progressive neuromuscular disease, is a leading genetic cause of death in infants, and 5q SMA is the most common form of the disease, Roche said.
Swiss pharmaceutical company Roche leads the clinical development of Evrysdi as part of a collaboration with PTC, a South Plainfield, N.J., pharmaceutical company, and the SMA Foundation.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 30, 2021 06:41 ET (10:41 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
